Data from University of Padova Provide New Insights into Chronic Lymphocytic Leukemia (Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review).
In: Hematology Week, 2024-04-18, S. 472-472
serialPeriodical
Zugriff:
A recent article from Hematology Week discusses new findings in chronic lymphocytic leukemia (CLL). The research highlights the development of innovative treatments for CLL, including novel combination therapies, CAR T cells, and bispecific monoclonal antibodies (BsAbs). The article emphasizes the need for a more personalized approach to CLL treatment, taking into account factors such as protein mutations, long-term toxicities, and costs. The researchers suggest that a measurable residual disease (MRD)-guided treatment cessation and re-initiation of targeted therapy may be a more feasible approach in the future. [Extracted from the article]
Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Data from University of Padova Provide New Insights into Chronic Lymphocytic Leukemia (Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review).
|
---|---|
Zeitschrift: | Hematology Week, 2024-04-18, S. 472-472 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-673X (print) |
Schlagwort: |
|
Sonstiges: |
|